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Lipopolysaccharides  (LPS)  of  Gram  negative  bacteria  are one  of the most  potent  stimulators  of  the  host
innate  immune  system  and  LPS  recognition  is  essential  for the  host  organism  to  clear  infections  of  invad-
ing  bacterial  pathogens.  Here  we  review  on the  latest  research  on  how  LPS  is sensed  by host  cells and
how  distinct  LPS  structures  differentially  modulate  the  strength  of  the  host  immune  response.  Much  is
known  about  host  immunological  reactions  towards  pathogens  via  recognition  of  their  LPS, as well  as
strategies  of  pathogens  to modulate  their  LPS  structure  in  order  to evade  the  immune  system.  However,
less  is known  about  differential  sensing  of lipopolysaccharides  of  commensal  bacteria  in the intestine
and  how  this  contributes  to manifestation  or destruction  of the  intestinal  homeostasis.  LPS sensing  is
necessary  to  ﬁght  pathogens.  However,  sensing  of  LPS  of  gut  commensal  bacteria  can  simultaneously  be
disadvantageous  for the  genetically  predisposed  host,  since  this  might  lead  to damage  of  the  intestinal
homeostasis  and  therefore  to chronic  intestinal  inﬂammation.  However,  less  immunogenic  LPS  could
also serve  as  therapeutics  to  antagonize  an overreacting  innate  immune  system.  Therefore,  commensal
gut  bacteria-derived  LPS  could  prevent  from  uncontrolled  intestinal  immune  response  in the  intestine
which  makes  LPS  an attractive  therapeutical  approach  to treat  e.g. IBD.
©  2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC. Introduction
Lipopolysaccharides fulﬁl two major functions. First, the LPS
nchored in the outer bacterial membrane provides a protective
unction for Gram negative bacteria and therefore acts as a defence
echanism against harsh environmental conditions. It provides a
arrier against surrounding stress factors which therefore makes
PS indispensable for bacterial viability in various distinct ecosys-
ems (Silipo et al., 2012). By substituting the lipid A sugar moieties
ith phosphate groups, the bacterium achieves to create a nega-
ively charged outer membrane which can therefore interact with
ivalent cations present in the surrounding milieu. This plays
n important role for the rigidity and the tightness of the outer
embrane and hence mediates bacterial resistance to external
tress factors (Alexander and Rietschel, 2001). Second, LPS is one
f the most conserved structures within all Gram negative bac-
erial species. This makes LPS an important pathogen associated
olecular pattern (PAMP) to be recognized by the mammalian
nnate immune system which can subsequently initiate the clear-
nce of a bacterial infection. This important immunological reaction
∗ Corresponding author. Tel.: +49 70712982351.
E-mail address: julia-stefanie.frick@med.uni-tuebingen.de (J.-S. Frick).
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438-4221/© 2016 The Authors. Published by Elsevier GmbH. This is an open acces
y-nc-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
contributes to the manifestation of relatively conserved molecular
structures in mammals for the recognition of this PAMP (Akira and
Takeda, 2004). A timely recognition and sensing of LPS of invading
Gram negative bacteria strongly accounts for host immune sys-
tem activation (Netea et al., 2002). However, the initiated immune
response has to be balanced. Uncontrolled bacterial overgrowth
within the mammalian body usually leads to the release of large
amounts of non-membrane bound LPS which can, in turn, result in
exaggerated systemic host immune responses. In severe cases, this
leads to septic shock with fatal consequences for the host (Bone,
1991; Bone et al., 1997).
2. Structure of lipopolysaccharides
LPS consists of three genetically, biologically and chemically
distinct domains (Alexander and Rietschel, 2001) (Fig. 1): (I) the
more or less acylated and phosphorylated lipid A being anchored
in the bacterial outer membrane, (II) the core oligosaccharide
linked by 3-deoxy-d-manno-oct-ulosonic acid (Kdo) with lipid A
and (III) the so-called O-antigen or O-speciﬁc polysaccharide, with
the latter two pointing to the aqueous environment. Lipopolysac-
charides that comprise all three regions are called smooth (S)-form
LPS, while LPS lacking the O-antigen are named rough (R)-form
LPS or lipooligosaccharide (LOS) (Fig. 1). The lipid A structure in
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Fig. 1. Schematic diagram of the general structure of lipopolysaccharides of Gram neg-
ative bacteria. Lipolysaccharides of Gram negative bacteria consist of three main
subunits (from bottom to top): lipid A, the core region and the O-antigen. Lipid A
and the core-region form rough (R)-type LPS. Lipid A, the core-region and the O-
antigen together form smooth (S)-type LPS. The number and chemical structure
of  the acyl chains can vary. Sugar moieties are depticted as hexagons in different
colours. The number and chemical structure of these sugar moieties can vary.
Fig. 2. Detailed Structure of E. coli lipid A. E. coli lipid A contains a (1 → 6)-linked glu-
cosamine disaccharide backbone (light brown). The hydroxyl group (light yellow)
of  the distal glucosamine links lipid A to the Core region. The two phosphate groups
are depicted in light green. Primary acyl chains (light grey) are directly linked to the
sugar moieties, secondary acyl chains (light red) are esteriﬁed with the hydroxyl
groups of primary acyl chains. All primary acyl chains of E. coli lipid are hydrox-
ymyristates, one of the two secondary acyl chains is myristate while the other one
being laurate.
general is highly conserved, which is important for host receptor
recognition.
3. Lipid A
Basically, lipid A is made up of a ˇ(1 → 6)-linked glucosamine
disaccharide backbone which is mostly phosphorylated at position
1 and 4′ of the saccharides and acylated at positions 2 and 3 of each
monosaccharide portion (Galanos and Freudenberg, 1993; Homma
et al., 1985; Kotani et al., 1985).
Usually, lipid A is hexaacetylated, meaning that six acyl chains of
variable length are esteriﬁed with the disaccharide backbone. Pri-
mary acyl chains are directly esteriﬁed with the sugar moiety while
so-called secondary acyl chains form ester bonds with hydroxyl
groups of primary acyl chains. “Symmetrically” acetylated lipid
A means that each glucosamine moiety carries the same number
of acyl chains. Escherichia coli LPS is an example for containing an
“asymmetrically” acetylated lipid A, since 4 of its 6 acyl chains are
carried by the ﬁrst glucosamine. Lipid A is embedded in the outer
leaﬂet of the bacterial outer membrane through electrostatic and
mainly hydrophobic interactions. Here, the diglucosamine part of
the lipid A is orientated towards the exterior environment while the
lipid A acyl chains point to the hydrophilic interior of the membrane
(Raetz and Whitﬁeld, 2002). Fig. 2 illustrates the detailed structure
of E. coli lipid A which is considered to be the prototype form of all
lipid A structures. Its two glucosamine residues are each substi-
tuted by a phosphate residue at positions 1 and 4′, respectively. The
hydroxyl groups at positions 2 and 3 of each monosaccharide are
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steriﬁed with hydroxymyristate, a saturated acyl chain with 14
arbon atoms, as primary acyl chain. Two additional secondary acyl
hains, laurate (C12) and myristate (C14), are coupled to hydrox-
myristates at positions 2′ and 3′ (Raetz and Whitﬁeld, 2002)
Fig. 2).
However, Lipid A structures widely vary among the differ-
nt bacterial species. Sometimes there are even more than one
ifferent lipid A structure within a single species (Raetz and
hitﬁeld, 2002). The sugar moieties of the saccharide backbone
re mostly 2-amino-2-deoxy-d-glucopyranoses (d-GlcpN) like in
. coli lipid A, but can also be, i.e. 2,3-diamino-2,3-dideoxy-d-
lucopyranose (d-GlcpN3N) containing an additional amino group
Molinaro et al., 2015; Roppel and Mayer, 1975). Other poten-
ial differences refer to the number, position and length of the
steriﬁed acyl chains, the presence of charged groups on the polar
eads as well as the number of phosphate groups coupled to the
isaccharide backbone (Raetz et al., 2007). The lipid A part of
PS is coupled to the core region through linkage via the non-
educing distal amino sugar of lipid A (Molinaro et al., 2015)
Fig. 2).
In E. coli lipid A, C12 and C14 acyl chains are the only ones being
steriﬁed with the disaccharide backbone (Fig. 2). However, other
acteria can provide differentially acylated lipid A which is sup-
osed to be mediated by other enzymes than the ones in E. coli
hich are speciﬁc for substituting C14 and C12. However, it could
e demonstrated that in Bacteroides fragilis and Bordetella pertussis,
he enzymes catalysing the acylation of the sugar moieties seem
o be multifunctional, therefore being able to recognize more than
ne speciﬁc acyl chain as a substrate (Bainbridge et al., 2008; Sweet
t al., 2002).
The number of acyl chains esteriﬁed with the disaccharide back-
one varies among the lipid A of different bacterial species. As
entioned above, the prototype hexaacylated lipid A contains six
cyl chains. However, certain bacterial species can provide “under-
cylated” lipid A structures, like tetraacylated Helicobacter pylori
ipid A (Mattsby-Baltzer et al., 1992; Moran et al., 1997) (Fig. 4),
r even “overacylated” structures like heptaacylated Acinetobacter
pp. lipid A (Leone et al., 2006, 2007).
The phosphorylation pattern of the disaccharide backbone is
lso not conserved among different bacterial species. As phos-
hate groups are negatively charged, a more or less phosphorylated
ipid A allows bacteria to change the net charge of their surface.
his surface net charge may  vary considerably dependent on envi-
onmental factors like temperature, pH value or, important for
mmune evasion, the presence of antibiotics and antimicrobial pep-
ides (AMPs). The phosphate groups can mediate interactions with
eighbouring phosphorylated lipid A structures via divalent cations
eing present in the surrounding environment. These interactions
onsiderably increase the stability of the bacterial outer mem-
rane and reduce the permeability of the cell wall (Molinaro et al.,
015).
. Core and O-antigen
The core moiety of LPS starts with at least one residue of 3-
eoxy-d-manno-oct-ulosonic acid (Kdo) which is directly linked to
ne of the sugar moieties of lipid A (Figs. 1 and 2). The core contains
p to 15 sugar residues and provides antigenic properties in the case
f a missing O-antigen (rough-type LPS) (Caroff and Karibian, 2003).
he O-antigen, sometimes also named O-speciﬁc polysaccharide or
imply “glycan” consists of repeating units of usually not more than
ve sugar units. The O-antigen can only be found in smooth type LPS
here it determines its antigenic properties (Raetz and Whitﬁeld,
002).ical Microbiology 306 (2016) 290–301
5. Molecular weight and micelle formation of isolated LPS
Usually, LPS is anchored in the bacterial outer membrane. How-
ever, for immunological sensing by the host immune system it
has to be released from the bacterial membrane. The exact con-
formation of isolated, non-bacterially attached, LPS is not easy
to determine. However, this is an important issue for in vitro
experiments using isolated LPS in aqueous solutions. Due  to its
amphiphilic structure, with the acyl chains of the lipid A form-
ing the hydrophobic part and the sugar residues of lipid A, the
core and the O-antigen building up the hydrophilic part, isolated
LPS rarely forms monomers in any solvent. Therefore, molecular
weight determination of either smooth or rough LPS is not trivial.
Dependent on the presence of divalent cations, detergents or the pH
value of the solvent, these large amphiphilic molecules form either
monomers, micelles or even vesicles. The critical LPS concentration
in aqueous solutions for micelle formation is stated to be 11 g/mL
(Aurell and Wistrom, 1998). Additionally, micelle formation capac-
ity is dependent on the structure of LPS, especially if it consists of
the S- or R- form. These micelles usually provide low solubility in
any solvent (Molinaro et al., 2015). However, the typical molecular
weight of monomeric S-form LPS of E. coli is reported to be between
11.8 and 18 kDa.
6. Biosynthesis of lipopolysaccharides of Gram negative
bacteria
The biosynthesis of hexaacetylated E. coli LPS has been described
in detail in 2002 by Raetz and Whitﬁeld (Raetz and Whitﬁeld, 2002).
Brieﬂy, the formation of Kdo2-substituted lipid A includes nine
enzymatic steps catalyzed by the enzymes LpxA, LpxB, LpxC, LpxD,
LpxH, LpxK, LpxL, LpxM and WaaA. This Kdo2 substituted lipid A
is synthesized in the bacterial cytosol and acyl chain substitution
involves the aid of bacterial acyl carrier proteins. Lipid A-Kdo2 is
completely synthesized in the cytosol either by soluble cytosolic
proteins or enzymes that are associated with the cytosolic part of
the inner bacterial membrane (Carty et al., 1999; Clementz et al.,
1996, 1997; Garrett et al., 1997; Vorachek-Warren et al., 2002).
The LPS core region is also synthesized in the cytosol. Lipid A-Kdo2
and the core region together form the rough-type (R-) LPS which
is transported across the inner membrane into the periplasmatic
space. Once located there, R-type LPS can either be directly inserted
into the outer leaﬂet of the outer bacterial membrane or it can be
converted into the S-(smooth) type LPS in the periplasmatic space
before being shuttled to the outer membrane. The ﬂipping of the
lipid A coupled LPS core is carried out by MsbA, an ATP-binding cas-
sette (ABC) transporter protein (Karow and Georgopoulos, 1993;
Zhou et al., 1998).
Although this describes only the events during biosynthesis
of LPS in E. coli, the general mechanisms seem to be conserved
among most Gram negative bacteria. Bioinformatics-based stud-
ies revealed that many Gram negative bacteria share enzymes like
the ones that are used in E. coli for LPS biosynthesis. But since
lipid A structures differ between distinct bacteria, alterations in the
structure are supposed to be due to genetic and/or environmental
differences or inﬂuences (Molinaro et al., 2015; Raetz et al., 2007).
7. Extracellular sensing of LPS through recognition by the
MD-2/TLR4 receptor complex
Long time, Toll-like receptor 4 (TLR4) was  supposed to be the
sole LPS sensor in mammalian organisms. TLR4 is a transmembrane
protein composed of 22 leucine-rich repeats (LRRs), one transmem-
brane domain and a cytosolic Toll/IL-1 receptor (TIR) domain, the
latter being a common feature in all TLRs. LPS is anchored in the
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acterial outer membrane. However, for being recognized by the
ost immune system, LPS has to be removed from the membrane
r membranous structures. This can either happen indirectly by
acterial cell death leading to a release of LPS or directly by the sol-
ble host protein lipid A-binding protein (LBP), a lipid transferase
hat is able to remove LPS molecules from the bacterial membrane
Miyake, 2006). LBP is present in the serum to sense bacterial pres-
nce in the blood. Additionally, LBP is secreted into the intestinal
umen where it is involved in sensing not only invading pathogens,
ut also commensal-derived LPS (Hansen et al., 2009) (Vreugdenhil
t al., 2000). In general, commensal intestinal bacteria can be sub-
ivided into two distinct groups, dependent on their potential to
nduce disease under certain circumstances: (1) symbiotic bacteria
hat never induce disease and (2) pathobiontic bacteria which are
otentially able to induce pathological immune reactions. Sensing
f LPS molecules from these two different bacterial subgroups is
mportant for a balanced intestinal immune system. This fact makes
BP essential for the maintenance of the intestinal homeostasis. LBP
ransports monomeric lipid A molecules to CD14. CD14 can either
e a membrane-anchored protein of TLR4-expressing cells or can
e secreted into the environment as a soluble protein. The pres-
nce of CD14 is important for LPS sensing, since it increases the
usceptibility of TLR4-expressing cells to LPS by factor 102 to 103
Wright et al., 1990). CD14-associated monomeric LPS is then shut-
led to MD-2 (Fig. 3A). Like CD14, MD-2 can be a soluble protein
ecreted into the cell exterior or it can be permanently attached
o a TLR4 monomer via hydrogen bonds (Kim et al., 2007; Visintin
t al., 2003). Binding of LPS to MD-2 leads to formation of a het-
rooligomeric protein complex consisting of two  MD-2 and two
LR4 molecules (Fig. 3A). This protein complex formation is ini-
ially induced through interaction at the extracellular domains.
hese extracellular protein-protein-interactions, in turn, result in
imerization of TIR-domain containing intracellular cytosolic parts
f the TLR4 receptors leading to Myeloid differentiation primary
esponse gene 88 (MyD88)- or TIR-domain-containing adapter-
nducing interferon- (TRIF)-dependent downstream signalling
Molinaro et al., 2015) (Fig. 3A). Binding of LPS to MD-2 leads to
onformational changes within MD-2 therefore promoting MD-2
inding to the ectodomain of TLR4 (Ohto et al., 2007, 2012). In 2009,
ark et al. (2009) revealed interesting detailed informations on the
inding conditions within a crystallized hexaacylated LPS-MD-2-
LR4 complex with both, murine and human TLR4 ectodomains. In
eneral, ﬁve of the six acyl chains of hexaacylated LPS are buried
nside a binding grove in the interior of MD-2. The sixth acyl chain
s located on the surface of MD-2 and partially exposed to the
urrounding solvent. In combination with hydrophobic residues
f MD-2, this 6th acyl chain promotes intermolecular interactions
ith TLR4 (Jin and Lee, 2008; Ohto et al., 2012). Taken together, the
nitial binding of LPS to MD-2 creates a new binding interface for
D-2 and therefore promotes MD-2 binding to TLR4 (Park et al.,
009). The resulting conformational changes within this complex
ead to dimerization of the C-termini of the TLR4 ectodomaines.
his event is supposed to mediate the dimerization also of the
ytosolic TIR domains of the TLR4 which initializes intracellular
ownstream signalling (Jin and Lee, 2008; Kim et al., 2007; Ohto
t al., 2012) (Fig. 3A). Taken together, MD-2 binding of lipid A is
ssential for TLR4-mediated LPS recognition. However, LBP and
D14 are supposed to be important for LPS sensing at low LPS
oncentration whereas they seem to be dispensable at high concen-
rations (Wurfel et al., 1995; Wurfel and Wright, 1997). Activation
f the TLR4-receptor complex results in an activation of more than
03 genes (Bjorkbacka et al., 2004) and promotes, i.e. the secre-
ion of pro-inﬂammatory cytokines like TNF, IL-6, IL-1 as well
s in enhanced production of the superoxide anion O2−, hydroxyl
adicals, NO and antimicrobial peptides (AMPs) (Ohto et al., 2007;
oltorak et al., 2000) (Fig. 3A).ical Microbiology 306 (2016) 290–301 293
8. Intracellular sensing of LPS through recognition by
cytosolic caspase-11
Caspases are intracellular cysteine proteases. The so-called
“inﬂammatory caspases” comprise a certain subset of these
enzymes which are critical for clearance of microbial infections
and initiation of the host immune system to ﬁght pathogens
(Lamkanﬁ et al., 2002; Martinon and Tschopp, 2004). Among oth-
ers, murine caspases 1, 4, 5 and 11 as well as human caspases
4 and 5 are considered to be such inﬂammatory caspases. They
all have in common that they are synthesized as proteolytically
inactive zymogens, needing proteolytic cleavage to induce enzy-
matic activity. Furthermore, they share an N-terminal domain
responsible for protein-protein interactions called caspase activa-
tion and recruitment domain (CARD). All genes of inﬂammatory
caspases are encoded in an inﬂammatory gene cluster. Once
activated, inﬂammatory caspases lead to the maturation of the
pro-inﬂammatory cytokines IL-1 and IL-18 and induce a special
kind of cell death, pyroptosis. Both mechanisms are mediated by
activation of cytosolic inﬂammasomes. Inﬂammasome activation
can be carried out through two different mechanisms: the canon-
ical and non-canonical way. The classical, or “canonical” way to
activate inﬂammasomes in a caspase-dependent manner, involves
proteins like Nod-like receptor protein 3 (NLRP3) or NLR family
CARD domain-containing protein 4 (NLRC4) engaging the intracel-
lular adaptor protein NLR family CARD domain-containing protein
4 (ASC) resulting in an activation of caspase-1 (Casp1) which leads
to a Casp1-catalyzed cleavage of IL-1 and IL-18 followed by secre-
tion of the mature cytokines (Mariathasan et al., 2006; Martinon
et al., 2006; Schroder and Tschopp, 2010). The non-canonical way
includes Casp1 activation with the requirement of Casp11 (Wang
et al., 1996). Interestingly, Casp11 can directly sense the presence
of cytosolic lipid A independently from TLR4 recognition but also
leading to inﬂammasome activation and consequently to IL-1 and
IL-18 secretion as well as pyroptosis (Fig. 3B).
The non-canonical inﬂammasome activation requires two inde-
pendent activation steps: First, a priming signal that leads to
an increase in intracellular expression of inﬂammasome compo-
nents like Casp1, NLRP3, ASC and Casp11. This initial event can
be lipid A binding to TLR4 (Raetz and Whitﬁeld, 2002) which efﬁ-
ciently enhances Casp11 gene transcription (Hagar et al., 2013;
Kayagaki et al., 2013; Wang et al., 1996). However, the prim-
ing event is not restricted to TLR4 recognition of lipid A. In fact,
activation of TLR2 and/or TLR7 by other bacterial components is
sufﬁcient to act as such a priming signal (Takeuchi and Akira,
2010). Second, after the priming event, intracellularly located LPS
can directly bind to Casp11 leading to its activation which sub-
sequently results in inﬂammasome activation. It could already be
shown that this Casp11-mediated non-canonical inﬂammasome
activation, independent of TLR4 activation, plays an important role
during bacterial challenge of the host with pathogens like Shigella
ﬂexneri (Rathinam et al., 2012), Salmonella typhimurium (Broz et al.,
2012a), Legionella pneumophila (Case et al., 2013) or Burkholderia
thailandiensis (Aachoui et al., 2013) but is also important for sensing
the LPS of gut commensals like E. coli (Kayagaki et al., 2013). Fur-
thermore, it seems that Casp11-mediated sensing of Gram negative
bacteria is not just an alternative to the TLR4-mediated way but
rather seems to be critical for an adequate response of the immune
system to these bacteria (Aachoui et al., 2013; Broz et al., 2012b;
Kayagaki et al., 2011; Rathinam et al., 2012).
But how can lipid A of non-invading bacteria like E. coli be sensed
intracellularly by cytosolic inﬂammasome components? As known
so far, Casp11 non-canonical inﬂammasome activation mostly
occurs in macrophages in mice, although a recent publications
reports on Casp11 expression in mouse epithelial cells (Knodler
et al., 2014). Macrophages are phagocytes which can include
294 A. Steimle et al. / International Journal of Medical Microbiology 306 (2016) 290–301
Fig. 3. Molecular mechanisms of extracellular and intracellular sensing of bacterial LPS. (A) Extracellular LPS sensing. The host lipid binding protein (LBP) samples LPS from the
outer  membrane of Gram negative bacteria and mediates its transport to host CD14. CD14 can either be soluble (sCD14) or anchored in the membrane of TLR4 expressing
cells.  CD14 shuttles LPS to the TLR4 coreceptor protein MD-2 which initiates a conformational change in MD-2 and TLR4, resulting in dimerization of the extracellular and
subsequently of the intracellular TIR domains. TIR domain dimerization mediates downstream signaling leading to enhanced expression of more than 1000 different genes.
(B)  Intracellular LPS sensing. Left side: LPS that is present in the extracellular space can enter (for example by, but not exclusively due to, receptor-mediated endocytosis)
the  vacuoles of caspase-11 (Casp11) expressing cells. LPS escapes the vacuoles via a yet unidentiﬁed mechanism. Right side: Gram negative bacteria can be sampled by
phagocytotic cells like Casp11 expressing macrophages. The LPS of non-cell invading bacteria or whole cell invading bacteria are relieved into the cytosol. Both: LPS present
in  the cytosol actively binds to the CARD domain of Casp11 leading to Casp11 oligomerization that results in Casp11 activation. By a yet unknown mechanism, this Casp11
activation results in inﬂammasome assembly resulting in Caspase-1 (Casp1) mediated secretion of the pro-inﬂammatory cytokines IL-1 and IL-18. Casp11 oligomerization
can  also lead to pyroptosis, a special kind of cell death.
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xtracellular bacteria into vacuolar phagolysosomes. Some bacte-
ia, which are specialized in intracellular replication, like Burkholde-
ia spp. can actively escape the phagosomes into the cytosol of
ost macrophages where they can trigger LPS-dependent Casp11
ctivation (Aachoui et al., 2013). Salmonella typhimurium is able to
upture the membrane of the bacteria-containing vacuole with the
se of Guanine-binding protein 2 (GBP2). However, the presence
f GBP2 is obviously dispensable for Casp11-mediated sensing of
. typhimurium LPS (Kayagaki et al., 2013), although other studies
eport GBPs to be critical for the release of vacuole content (Meunier
t al., 2014; Pilla et al., 2014). How LPS of other Gram negative bacte-
ia which are not specialized in host cell invasion like E. coli or Cit-
obacter rodentium (Kayagaki et al., 2013; Meunier et al., 2014) can
e translocated from the vacuole to the cytosol of host macrophages
n order to be sensed by Casp11 is unknown so far (Fig. 3B). Most
n vitro studies therefore used methods like electroporation or
ransfection to make cytosolic Casp11 capable of LPS sensing.
It is already clear that, lipid A is the decisive part for intracellular
asp11-mediated LPS sensing (Hagar et al., 2013; Kayagaki et al.,
013), just like it is the case for TLR4-mediated recognition of
PS. It could also be shown that the categories “antagonistic” and
agonistic” in terms of LPS endotoxicity can also be referred to
ipid A-induced Casp11 activation, since lipid A structures that
re weakly agonistic or antagonistic for TLR4 activation also fail
o induce Casp11 activation (Hagar et al., 2013; Kayagaki et al.,
013). This is not due to a lower afﬁnity for lipid A to Casp11
ince it could be demonstrated that these less agonistic lipid A
tructures efﬁciently bind to Casp11 (Shi et al., 2014). However, it
s not known if the same structural criteria for being agonistic or
ntagonistic, which are valid in case of MD-2/TLR4-mediated lipid
 sensing, also counts for Casp11. When lipid A is located in the
ytosol, it is able to directly bind to Casp11 with the help of the
asp11- intrinsic CARD domain subsequently leading to Casp11
ligomerization (Shi et al., 2014). The exact mechanisms behind
hese ﬁndings are not understood so far. However, it is clear that
his lipid A- induced Casp11 oligomerization leads to proteolytical
ctivation of Casp11 within the oligomer (Shi et al., 2014; Shin
t al., 2007). Lipid A binding to Casp11 is highly speciﬁc, since no
ther LPS component could be shown to interact with Casp11 and,
nversely, no other caspase interacts with lipid A (Shi et al., 2014).
aspase-11 (Casp11) was initially discovered by Wang et al (Wang
t al., 1996) and two corresponding orthologues of murine Casp11
ould be discovered in humans: caspase-4 (Casp4) and caspase-5
Casp5) (Stowe et al., 2015).
. Other host proteins being involved in LPS sensing
Apolipoprotein CI (ApoCI) is a small apolipoprotein which is
resent in the serum. It has been shown to provide an LPS-binding
otif with which it is able to bind to bacterial LPS, ﬁnally enhancing
n LPS induced inﬂammatory host response (Berbee et al., 2006). It
eems to act in a comparable way like LBP and promotes CD14/MD-
/TLR4-mediated LPS signalling (Berbee et al., 2010). By its strong
fﬁnity to bacterial LPS it enhances the residence time of LPS in the
irculation (Berbee et al., 2006). This makes ApoCI an important fea-
ure to protect from fatal sepsis, since the prolonged residence time
nhanced the access for LPS-sensing blood cells in order to ﬁght
nvading pathogens, as demonstrated in a Klebsiella pneumoniae
epsis model (Berbee et al., 2006). Acyloxyacyl hydrolase (AOAH) is
n enzyme, expressed in host antigen presenting cells, that renders
gonistic lipid A into non-TLR4 signaling structures by removing
cyl chains from the lipid A disaccharide backbone (Munford and
all, 1986). AOAH is a critical enzyme when it comes to inactiva-
ion of agonistic LPS of pathogens and endotoxin tolerance. Such a
olerance towards pathogen-derived lipid A diminishes theical Microbiology 306 (2016) 290–301 295
immune response of the host to ﬁght these invading microbes
(Lu et al., 2008). The restoration of a powerful immune response
is dependent on the inactivation of the pathogen’s lipid A, mak-
ing AOAH crucial in this context (Lu et al., 2008). The impact of
AOAH on inactivation of commensal lipid A is less clear. It could
be shown that AOAH is preferentially expressed in a Th17-immune
response mediating dendritic cell subpopulation and that AOAH
deﬁciency favours induction of Treg cells over induction of Th17 cells
(Janelsins et al., 2014). However, the correlation between AOAH
activity, microbiota composition (and therefore lipid A structures)
and the outcome of inﬂammatory bowel disease still needs to be
elucidated.
10. Immunogenicity of lipopolysaccharide
As already mentioned, LPS structure, especially its lipid A chem-
istry, differs among distinct bacterial species. Indeed, the exact
LPS structure, and in this context mainly the lipid A structure,
determines LPS immunogenicity and is therefore decisive for its
function (Brandenburg et al., 1993; Seydel et al., 2000). LPS which
triggers a strong pro-inﬂammatory reactions of host cells are
named “agonistic” lipolysaccharides. In contrast, structurally dif-
ferent lipid A can also result in weak inﬂammatory host responses,
hence being called “weak agonistic” or it can even completely
block any pro-inﬂammatory reactions by binding to correspond-
ing host receptors. The latter lipopolysaccharides are therefore
called “antagonistic”. Most Gram negative bacteria express ago-
nistic hexaacylated LPS like E. coli LPS, which is one of the most
potent agonists of the human innate immune system (Beutler and
Rietschel, 2003; Raetz and Whitﬁeld, 2002; Zahringer et al., 1994)
(Fig. 4A). Usually the number of lipid A acyl chains directly cor-
relates with the ability to induce cytokine production whereas
the hexaacylated forms usually are the most immunostimulat-
ing ones (Munford and Varley, 2006). Within a biological system,
distinct lipid A structures compete for binding to host receptors.
Antagonistic lipid A might therefore compete with agonistic LPS
for host receptor binding. Hexaacylated lipid A seems to promote
the strongest proinﬂammatory immune reactions after binding to
TLR4. This is due to the fact that the ﬁrst ﬁve acyl chains are buried in
a hydrophobic cavity of the TLR4 adaptor molecule MD-2 while the
sixth chain mediates the binding to TLR4, the precondition for TLR4-
mediated intracellular signalling (Maeshima and Fernandez, 2013;
Park et al., 2009). Therefore, TLR4-mediated signalling usually is
drastically reduced if this sixth acyl chain is missing. However, due
to the already mentioned differences in the structures of the lipid
A binding cavity of the TLR4 receptor between different mammal
species, distinct lipid A structures can provide a different immuno-
genic potential between these species. Fig. 4 summarizes different
lipid A structures and their corresponding agonistic or antagonistic
properties.
Not only acyl chains contribute to the immunogenic properties
of lipid A, but also the number of phosphate groups. A deletion
of a phosphate group can result in a loss of the endotoxic activ-
ity (Rietschel et al., 1994). Most lipid A structures contain two
phosphate residues, one on each sugar moiety. However, some bac-
terial lipid As lack one or even both of them, therefore altering
its immunogenic potential. For example, Francisella tularensis lacks
one or both phosphate groups and this is considered to be, at least
in part, the reason for its weak agonistic property (Molinaro et al.,
2015) (Fig. 4E). Furthermore, the non-phosphorylation might also
be seen as an immune evasion strategy for certain bacteria since
some antimicrobial peptides (AMPs) speciﬁcally target negative
charges on bacterial surfaces and a loss of negatively charged phos-
phate residues therefore renders bacteria to be invisible for these
AMPs.
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Fig. 4. Different lipid A structures of various bacteria and their immunogenic potential. (A) prototype E. coli lipid A. (B–C, E, G–K) lipid A structures of other bacteria. (D) structure
of  antagonistic lipid IVa. (F) structure of the chemically synthesized TLR4 antagonist Eritroran. Immunogenic phosphate groups are highlighted in light red. The bold red
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1. Immune-evasion
Induction of antibacterial defence by triggering inﬂammatory
ost responses is a crucial function of the innate immune system in
esponse to invading bacteria. This reaction prevents the spreading
f bacteria and suppresses the bacterial growth. In many infections
ith pathogens, the innate immune responses slow the progress
f infection and allow for the adaptive immune responses to
evelop (Montminy et al., 2006). Suppressing or evading the host
mmune responses is a successful strategy of pathogenic bacteria,
nown as immune-evasion (Montminy et al., 2006). Immuneain. Structural differences of the acyl chains compared to prototype agonistic E. coli
compared to prototype agonistic E. coli lipid A are highlighted in light yellow. The
nic behaviour due to TLR4 binding. See text for details.
evasion strategies based on lipid A modiﬁcation help to promote
the survival of Gram negative bacteria by evading host immune
responses that are directed against bacterial invasion, chronic
persistence or susceptibility to cationic antimicrobial peptides
(CAMP) (Needham and Trent, 2013).
As mentioned above, the acylation pattern of lipid A varies
between species and is heterogeneous even within a single
species (Dixon and Darveau, 2005; Raetz and Whitﬁeld, 2002;
Zähringer and Rietschel, 1999). Environmental conditions are
known to inﬂuence the lipid A structure by modulating for
example the number, composition and location of acyl chains
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hereby affecting the biological activity of lipid A. The production
f weak stimulatory lipid A is thought to be involved in the
irulence of several Gram negative pathogens (Dixon and Darveau,
005).
An impressive and well-characterized example of lipid A mod-
ﬁcation as immune evasion mechanism represents Yersinia pestis
Montminy et al., 2006). Y. pestis grown at 21–28 ◦C (ﬂea tempera-
ure) expresses hexaacylated lipid A structures (Fig. 4H), but these
ipid A structures are mainly tetraacylated at 37 ◦C (host tempera-
ure) (Kawahara et al., 2002; Knirel et al., 2005; Rebeil et al., 2004)
Fig. 4J). Although hexaacylated lipid A is normally a strong activa-
or of human TLR4, tetraacylated lipid A has a signiﬁcantly lower
ctivity (Golenbock et al., 1991; Kawahara et al., 2002; Lien et al.,
000; Loppnow et al., 1989; Rebeil et al., 2004) and is thought to
ct as a TLR4 antagonist (Needham and Trent, 2013). To suppress
ocal inﬂammatory immune responses, Y. pestis uses several par-
llel mechanisms that individually are necessary for virulence like
.g. a type 3 secretion system (T3SS), releasing immunosuppress-
ve proteins (Nakajima et al., 1995). However, evading activation of
LR4 was shown to be an essential part of the Y. pestis immune eva-
ion. The ability of a Y. pestis mutant strain expressing lipid A with
n increased capacity to activate TLR4 at 37 ◦C was dominant over
he anti-host bacterial defences provided by the T3SS and other Y.
estis activities (Montminy et al., 2006). Hence, despite retention of
ultiple immune evasive proteins used by Y. pestis to suppress host
esponses, a strain producing hexaacylated lipid A and thus being
uickly detectable by means of TLR4-MD-2 failed to cause disease
Montminy et al., 2006).
Similar to Y. pestis, F. tularensis (Fig. 4E) shows a dynamic regu-
ation of lipid A acyl chain length according to temperature (Okan
nd Kasper, 2013; Needham and Trent, 2013). F. tularensis has
wo homologues of the essential lipid A biosytheses acyl trans-
erase LpxD, LpxD1/LpxD2, (Valentin-Hansen et al., 2007). LpxD1
as its optimum activity at 37 ◦C and consistent with this the lpxD1
utant is unable to express the modiﬁed lipid A with longer acyl
roups and is severely attenuated in mice (Okan and Kasper, 2013;
i et al., 2012) and is also more susceptible to antibiotics and CAMP
y reason of an increased membrane permeability (Li et al., 2012;
eedham and Trent, 2013).
Another example of evading the recognition of the host’s
mmune system by modifying the lipid A component of LPS is
. pylori.  Despite a robust host immune response, H. pylori per-
ists within the gastric niche and promotes a chronic infection
or the duration of the host’s life (Gaddy et al., 2015). H. pylori
ses two lipid A based immune evasion strategies, evasion of
etection by TLR4 and resistance to CAMP. The lipid A of H. pylori has
 unique structure and lower biological activity as compared to lipid
 from other bacteria, e.g. E. coli (Chmiela et al., 2014; Moran and
spinall, 1998; Muotiala et al., 1992). Interestingly H. pylori syn-
hesizes a hexaacylated lipid A but exhibits a tetraacylated lipid A
acking phosphate groups at its surface (Needham and Trent, 2013)
Fig. 4C). The structural differences are generated by the action of
everal enzymes including deacylation by LpxR and dephosphory-
ation by LpxE and LpxF (Gaddy et al., 2015; Needham and Trent,
013). Hence H. pylori provides a tetraacetylated antagonistic lipid
 structure (Fig. 4C) that not only prevents TLR4-mediated activa-
ion of the innate immune system (Moran et al., 1997; Ogawa et al.,
003; Raetz et al., 2007), but also from Casp11-mediated inﬂamma-
ome activation (Kayagaki et al., 2013) (Fig. 3B). Other examples for
nderacetylated antagonistic lipid A are Rhodobacter sphaeroides
Fig. 4G) and Rhodobacter capsulatus lipid A structures (Rose et al.,
995).Many Gram-negative bacteria utilize lipid A modiﬁcations to
urvive the antimicrobial peptide response imposed by the ver-
ebrate host. Altering the bacterial surface charge by e.g. adding
ositively charged moieties reduces the binding afﬁnity of cationicical Microbiology 306 (2016) 290–301 297
antimicrobial peptides with the bacterial outer membrane. An
important antimicrobial factor is calprotectin. It is a critical compo-
nent of the host nutrient withholding process, termed nutritional
immunity (Gaddy et al., 2015; Gebhardt et al., 2006; Urban et al.,
2009). One mechanism of nutritional immunity is the host induced
restricted access for bacteria to essential metals (Hood and Skaar,
2012). Calprotectin binds Zn2+ and Mn2+ with high afﬁnity which
starves bacteria of these essential metals, creating a Zn2+ and Mn2+
limited environment. Additionally, calprotectin exhibits antimicro-
bial activity against numerous Gram-positive and Gram-negative
bacteria (Corbin et al., 2008; Damo et al., 2013; Hood et al.,
2012; Liu et al., 2012; Lusitani et al., 2003; Sohnle et al., 2000;
Steinbakk et al., 1990). Moreover calprotectin has been demon-
strated to inhibit H. pylori growth and has the capacity to modify
the activity of the cag type IV secretion system. However H. pylori
is able to persist in the gastric niche despite this robust immune
response. One mechanism allowing for persistence is the modiﬁ-
cation of the H. pylori lipid A in response to calprotectin. Thereby
the lipid A modiﬁcation pathway is inﬂuenced by the host nutri-
tional immune response as the calprotectin dependent restricted
access to essential metals like Zn2+ and Mn2+ perturbs the function
of H. pylori enzymes involved in the lipid A modiﬁcation path-
way, resulting in increased bacterial ﬁtness and increased bioﬁlm
formation.
Salmonella enterica subsp. enterica serovar Typhimurium is an
intracellular pathogen which causes gastroenteritis in humans. In
S. typhimurium the modiﬁcation of lipid A is controlled by the
PhoPQ system which is activated by low Mg2+ concentrations or
CAMPs (Guo et al., 1997; Guo et al., 1998; Raetz et al., 2007), e.g.
by growing cells under Mg2+ limitation or during growth within
macrophage phagosomal vacuoles (Martin-Orozco et al., 2006). The
activation of the PhoPQ and the PmrAB systems results in an addi-
tion of phosphoethanolamine and aminoarabinose and to a PagP
and PagL dependent acyl chain remodelling (Richards et al., 2012).
In addition LpxO hydrolates S. typhimurium lipid A as part of a coor-
dinated stress response (Moreira et al., 2013; Needham and Trent,
2013).
Porphyromonas gingivalis which is considered to be an impor-
tant agent in human periodontal disease exhibits a very large
degree of ﬂexibility in the structure of its lipid A (Curtis et al.,
2011). It harbours di-and monophosphorylated and penta- and
tetraacylated moieties (Kumada et al., 1995) and in addition
a spectrum of nonphosphorylated lipid A species (Rangarajan
et al., 2008). Dependent on the temperature P. gingivalis shifts
the lipid A from an inert nonphosphorylated and antagonizing,
monophosphorylated, tetra-acylated structure at 37 ◦C to a
monophosphorylated, penta-acylated higher-potency TLR4 ago-
nistic structure at 41 ◦C (Curtis et al., 2011). In addition, the lipid
A structure of the tetra-acylated nonphosphorylated P. gingivalis
grown at 37 ◦C contributes to the resistance to CAMPs (Coats et al.,
2009).
12. Other antagonistic lipid A structures
Usually, pathogenic bacteria naturally provide antagonistic
lipid A structures as a strategy of immune evasion, since a non-
response towards their LPS renders them less visible for the host
immune system. One of the most known antagonistic lipid A
structures for the human TLR4 receptor complex is the so-called
lipid Iva (Fig. 4D). Its backbone structure strongly resembles the
structure of agonistic E. coli LPS. In fact, it constitutes a precur-
sor form of mature E. coli lipid A. However, due to a lack of
both secondary acyl chains (Fig. 4D) that are present in E. coli
lipid A (Fig. 4A), it provides strong antagonistic properties with
simultaneous high afﬁnity binding to MD-2 and therefore TLR4
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Beutler and Rietschel, 2003; Raetz and Whitﬁeld, 2002; Zahringer
t al., 1994). Although being a strong antagonist for the human
LR4 receptor complex, lipid IVa is a weak agonist for the murine
LR4 receptor complex. This is based in minor structural differ-
nces between human and murine MD-2. Whereas lipid IVa binding
o human MD-2 results in an upward shift of the phosphory-
ated disaccharide backbone mediating antagonistic properties, the
inding of lipid IVa to the murine MD-2 leads to a similar con-
ormation compared to agonistic hexaacylated lipid A (Ohto et al.,
012).
3. Endotoxicity of LPS as a determinant of intestinal
nﬂammation or homoeostasis
It is well accepted that in inﬂammatory bowel diseases (IBD),
hronic inﬂammatory disorders of the intestine, the mucosal
mmune system reacts inappropriately towards the intestinal
ommensal microbiota (Vijay-Kumar and Gewirtz, 2009). How-
ver no particular microbial species has been consistently linked
o IBD pathogenesis, but some symbiotic bacteria species have
een shown to prevent inﬂammatory host responses (Chassaing
nd Darfeuille-Michaud, 2011; Chow and Mazmanian, 2010;
evkota et al., 2012; Jeon et al., 2012; Round and Mazmanian,
009).
The mono-colonization of Il2−/− mice with E. coli is reported
o induce severe colitis, whereas monocolonization with Bac-
eroides vulgatus does not and B. vulgatus even inhibits the E. coli
nduced inﬂammation in co-colonized Il2−/− mice (Waidmann
t al., 2003). Recently we showed that a low endotoxicity of
he intestinal microbiota was associated with mucosal immune
omeostasis in a mouse model of chronic intestinal inﬂammation
Gronbach et al., 2014). T cell transplanted Rag1−/− harboring a
ow endotoxic complex intestinal microbiota, characterized by high
umbers of Bacteroidetes and low numbers of Enterobacteriaceae
id not develop colitis, whereas T cell transplanted Rag1−/− mice
arboring a high endotoxic complex intestinal microbiota, charac-
erized by high numbers of Enterobacteriaceae and low numbers of
acteroidetes developed severe intestinal inﬂammation (Gronbach
t al., 2014). In line with this, feeding of Rag1−/− mice, harboring
he low endotoxic microbiota with commensal but pathobion-
ic E. coli JM83 resulted in intestinal inﬂammation, whereas the
dministration of an E. coli JM83 mutant containing an acyl-
ransferase from P. gingivalis (E. coliMUT) protected Rag1−/− mice
arboring the high endotoxic microbiota from induction of dis-
ase (Bainbridge et al., 2006). We  isolated and puriﬁed LPS from
oth E. coliWT and E. coliMUT and characterized its fatty acid com-
osition. Investigations by high-resolution electrospray ionization
ourier transform ion cyclotron mass spectrometry revealed the
ame hexaacetylated lipid A molecules in both strains. In addi-
ion, E. coliMUT contained a major portion of lipid A, in which
 12 carbon atom laurate acyl chain is replaced by a 16 carbon
tom palmitate acyl chain (Gronbach et al., 2014) (Fig. 4A and
). This minor modiﬁcation in E. coli JM83 is reported to sig-
iﬁcantly affect host cell signaling (Bainbridge et al., 2006). To
erify the altered stimulatory capacity of LPSMUT compared with
PSWT, we used TLR4-overexpressing human embryonic kidney
ells (HEK293). Stimulation of cells with the modiﬁed LPSMUT
esulted in a signiﬁcantly reduced IL-8 secretion 4 h after stimu-
ation, as compared with LPSWT indicating a reduced endotoxicity
ut not TLR4 antagonism of the altered LPSMUT. Feeding of Rag1−/−
ice harboring the low endotoxic microbiota with LPSWT resulted
n severe intestinal inﬂammation, however challenging mice which
ere colonized with the high endotoxic microbiota protected
hese animal from induction of colitis (Gronbach et al., 2014). This
ata suggest that the ratio of high endotoxic and low endotoxicical Microbiology 306 (2016) 290–301
LPS is crucial for the regulation of the intestinal immune bal-
ance. A predominance of high endotoxic LPS might promote a
TH1/TH17 response, subsequently supporting intestinal inﬂamma-
tion, and a predominance of low endotoxic LPS might induce an
altered activation of the innate immune system, and either induc-
tion of regulatory T cells or prevention of a TH1/TH17 response,
associated with intestinal immune homeostasis (Gronbach et al.,
2014). Therefore LPS might act as a key microbial symbiosis fac-
tor that, depending on its structure, can induce or prevent bowel
inﬂammation by shaping the innate immunity via TLR4-dependent
signaling mechanisms (Gronbach et al., 2014; Yamamoto and Akira,
2009).
14. LPS as a potential drug for the treatment of
inﬂammatory bowel disease?
The role of LPS for the host immune system provides ambiva-
lent features. While LPS is essential for the host organism to sense
infections of bacterial pathogens at an early stage, therefore help-
ing to clear the infection, an imbalanced LPS sensing can have
severe effects for the host organism with fatal sepsis being the
most severe consequence. Blocking TLR4 mediated downstream
signaling has been implicated to be useful as a drug to prevent
from septic shock (O’Neill et al., 2009). Therefore, synthetic antag-
onistic lipid A structures were invented in order to block TLR4
receptor signaling, such as Eritroran (Fig. 4F). Eritroran strongly
prevents from binding of agonistic lipid A to MD-2 and there-
fore terminates MD-2/TLR4-mediated signaling in vitro, ex vivo
and in vivo (Mullarkey et al., 2003; Rossignol and Lynn, 2002;
Rossignol et al., 2004). Despite these ﬁndings, Eritroran failed to
improve survival in a phase III trial in patients with severe sep-
sis (Opal et al., 2013). Until now, it is not known why Eritroran
gavage failed to prevent from fatal sepsis. Possible explanations
might be the delayed administration of this strong TLR4 agonist
or a failure in trial design (Opal et al., 2013; Tse, 2013). Neverthe-
less, antagonistic lipid A structures still seem to be a promising
tool for the treatment of bacterially induced sepsis. This strategy
to prevent from an uncontrolled, or “imbalanced”, TLR4 signaling-
mediated immune response might also be an attractive approach to
deal with inﬂammatory disorders of the gut. Inﬂammatory bowel
disease develops from an uncontrolled immune response directed
towards the intrinsic microbiota. In this case, not pathogens are
the target of the immune system, but rather commensal bacte-
ria located in the intestine. It might therefore be possible that
antagonistic or weakly agonistic lipid A structures could prevent
from uncontrolled TLR4-mediated immune responses towards the
own microbiota. In fact, we  could already show that the lipid A
structure of commensal bacteria is a decisive trigger for the induc-
tion of colitis in a genetically predisposed host (Gronbach et al.,
2014).
Two main questions remain concerning the administration of
isolated LPS (or lipid A) for the treatment of IBD. (I) Which lipid A
structure might provide the best results and (II) is TLR4 blocking
really “the method of choice”?
The speciﬁc structure of lipid A can have profound and even
unpredictable effects upon TLR4 signaling. Although detailed stud-
ies about the interaction of lipid A with its corresponding MD-2
co-receptors are available (Ohto et al., 2012; Park et al., 2009),
the precise immunogenicity cannot be predicted from knowing the
structure alone. However, a recent report by Paramo et al. (2015)
means a major advance concerning this issue, since they manage
to predict the binding behaviour of lipid A structures to MD-2 by
measuring their potentials of mean force. The second question is
even more complicated to answer. It is possible that TLR4 blocking
might not restore homeostasis in every case, since TLR4 signaling
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eems to be important for the prevention of dextran sodium sul-
ate (DSS)- induced colitis in mice (Rakoff-Nahoum et al., 2006;
ittmann et al., 2015). Therefore, an antagonistic lipid A struc-
ure, completely preventing from TLR4 signaling, might not be the
ipid A of choice. Possibly, a rather weakly agonistic lipid A struc-
ure, allowing basic TLR4-mediated signaling, but preventing from
ncontrolled TLR4 activation might be a better tool. Additionally,
he recent discovery of caspase-11 as an intracellular lipid A bind-
ng LPS sensor (Kayagaki et al., 2011, 2013; Shi et al., 2014) leads
o the question, if blocking the TLR4 binding cavity is sufﬁcient to
nﬂuence LPS-mediated induction of the host immune system. As
escribed above, a block of TLR4 is not sufﬁcient to prevent from LPS
nduced Casp11-mediated inﬂammasome activation. Other bac-
erial components, largely present in the intestine, can activate
ther TLRs than TLR4 to induce an increase in cytosolic amounts
f Casp11 being a precondition for intracellular lipid A sensing.
herefore, a potential lipid A-derived drug needs to have access
o the cytosol of host target cells. Although being highly specu-
ative, this might be another explanation why Eritroran failed in
he clinical study since it was not granted access to the cytosolic
ompartment. This fact rises drug development to a severe chal-
enge and strategies need to be developed to target therapeutic
ipid A to the cytosolic compartment. Since it could be shown
hat lipid A structures that act antagonistically in TLR4-signaling
lso prevent from Casp11 oligomerization and activation despite
fﬁcient binding (Shi et al., 2014). Therefore, it seems that the
mmunogenicity of lipid A structure concerning TLR4 activation,
escribed by the terms agonistic and antagonistic, also accounts
or intracellular lipid A induced intracellular inﬂammasome acti-
ation.
There is an ongoing research for new lipid A structures in order
o be used as therapeutic. Although most research on this topic
ocuses on the treatment of sepsis, the idea behind it can easily
e transferred to the treatment of chronic inﬂammatory intesti-
al disorders. Besides synthetic or chemical development of lipid
 structure-related TLR4 antagonists, there is an ongoing interest
lso on LPS structures of more “exotic” bacteria and how they might
ontribute to a research progress on this topic. For example, Di
orenzo et al. (2014) identiﬁed a lipid A structure with strong antag-
nistic activity in a bacterium living in hot springs: Thermomonas
ydrothermalis (Fig. 4K). However, a closer and more detailed look
n the lipid A structures of symbiotic commensal bacteria might
e helpful for the development of a lipid A structure providing
eak agonistic activity to prevent from both, TLR4- and Casp11-
ediated, uncontrolled immune responses of the host organism
owards its own microbiota.
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